Sphera Funds Management LTD. bought a new stake in Molecular Templates Inc (NASDAQ:MTEM) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 400,000 shares of the biotechnology company’s stock, valued at approximately $2,156,000. Sphera Funds Management LTD. owned 1.13% of Molecular Templates as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in shares of Molecular Templates in the 2nd quarter valued at $138,000. Dimensional Fund Advisors LP increased its stake in shares of Molecular Templates by 168.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 71,266 shares of the biotechnology company’s stock valued at $373,000 after buying an additional 44,673 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Molecular Templates by 976.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 89,436 shares of the biotechnology company’s stock valued at $482,000 after buying an additional 81,128 shares during the period. Northern Trust Corp increased its stake in shares of Molecular Templates by 338.9% in the 2nd quarter. Northern Trust Corp now owns 97,228 shares of the biotechnology company’s stock valued at $509,000 after buying an additional 75,076 shares during the period. Finally, Nexthera Capital LP acquired a new stake in shares of Molecular Templates in the 2nd quarter valued at $902,000. 35.81% of the stock is owned by institutional investors.
In related news, Director David Hirsch purchased 365,000 shares of Molecular Templates stock in a transaction dated Friday, September 21st. The shares were acquired at an average cost of $5.50 per share, for a total transaction of $2,007,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Scott D. Morenstein purchased 545,454 shares of Molecular Templates stock in a transaction dated Tuesday, September 25th. The stock was bought at an average price of $5.50 per share, for a total transaction of $2,999,997.00. The disclosure for this purchase can be found here. 52.00% of the stock is owned by company insiders.
NASDAQ:MTEM opened at $4.39 on Friday. Molecular Templates Inc has a 12-month low of $3.87 and a 12-month high of $13.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.80 and a current ratio of 2.80. The firm has a market capitalization of $162.77 million, a PE ratio of -2.08 and a beta of 3.10.
Molecular Templates (NASDAQ:MTEM) last posted its quarterly earnings results on Thursday, November 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.15. Molecular Templates had a negative return on equity of 14.12% and a negative net margin of 118.65%. The business had revenue of $6.75 million for the quarter. Analysts forecast that Molecular Templates Inc will post -0.63 EPS for the current fiscal year.
Several equities research analysts have recently commented on MTEM shares. Laidlaw started coverage on Molecular Templates in a research note on Monday, October 8th. They issued a “buy” rating and a $18.00 target price for the company. Zacks Investment Research raised Molecular Templates from a “sell” rating to a “hold” rating in a research note on Wednesday, September 19th. Evercore ISI started coverage on Molecular Templates in a research note on Thursday, November 15th. They issued an “outperform” rating for the company. ValuEngine cut Molecular Templates from a “hold” rating to a “sell” rating in a research note on Tuesday, September 4th. Finally, Cowen started coverage on Molecular Templates in a research note on Tuesday, November 20th. They issued an “outperform” rating for the company. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $18.00.
Molecular Templates Profile
Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase I clinical trial for the treatment of relapsed/refractory non-Hodgkin's lymphoma and B-cell lymphoma.
Further Reading: Institutional Investors
Want to see what other hedge funds are holding MTEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Molecular Templates Inc (NASDAQ:MTEM).
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.